Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3199977 | 0.86 | ALDH1A1 (0.50) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL31050951 | 0.85 | LMNA (0.73) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL2327551 | 0.83 | LMNA (0.78) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL2973041 | 0.81 | LMNA (0.67) | LMNACYP1A2ALDH1A1TSHRALOX15 | |
| SCHEMBL3205666 | 0.81 | ALDH1A1 (0.53) | LMNAMMP1MMP2MMP3MMP8 | |
| Stearic Acid SCHEMBL2153198 | 0.81 | GPR84 (0.59) | LMNAMMP2HSD17B10CYP1A2ALDH1A1 | |
| Behenic Acid SCHEMBL16107136 | 0.81 | GPR84 (0.59) | LMNAMMP2HSD17B10CYP1A2ALDH1A1 | |
| SCHEMBL3210666 | 0.80 | ALDH1A1 (0.59) | LMNAMMP1MMP2MMP3MMP8 | |
| Hydrochloric Acid SCHEMBL8356777 | 0.80 | LMNA (0.64) | LMNACYP1A2ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL8358577 | 0.80 | LMNA (0.64) | LMNACYP1A2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848719-B1 | [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2012-02-01 | — | — | EP | claimed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | claimed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | claimed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | claimed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | claimed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | claimed |
| EP-2729459-B1 | SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-9199962-B2 | Substituted azaheterocycles for the treatment of cancer | MERCK PATENT GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20140221366-A1 | Substituted Azaheterocycles for the Treatment of Cancer | MERCK PATENT GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| EP-2729459-A1 | SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013004332-A1 | SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2013-01-10 | — | — | WO | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
| US-5229418-A | Histamine H-2 receptor antagonists, antiulcer | GLAXO GROUP LIMITED (GB) | 1993-07-20 | — | — | US | disclosed |
| EP-0454469-A1 | Carboxylic acid derivatives | GLAXO GROUP LIMITED (GB) | 1991-10-30 | — | — | EP | disclosed |
| US-4822529-A | QUATERNARY AMMONIUM ALKYL PHOSPHATES | TAKEMOTO YUSHI KABUSHIKI KAISHA (JP) | 1989-04-18 | — | — | US | disclosed |
| US-4727177-A | ANTISTATIC AGENTS | TAKEMOTO YUSHI KABUSHIKI KAISHA (JP) | 1988-02-23 | — | — | US | disclosed |
| EP-0240622-A1 | Antistatic agents for synthetic fibers and methods for producing such agents | Takemoto Yushi Kabushiki Kaisha (JP) | 1987-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | LMNA 2367/4885MMP1 2726/4885MMP2 2416/4885 |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | PDPK1, MTOR, RPS6KA2 | LMNA 4117/4885MMP1 763/4885MMP2 802/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | LMNA 277/4885MMP1 777/4885MMP2 1316/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | LMNA 1884/4885MMP1 2180/4885MMP2 2453/4885 |
| US-20140221366-A1 | Substituted Azaheterocycles for the Treatment of Cancer | CCNH, CCNA1, MYC | LMNA 3137/4885MMP1 3807/4885MMP2 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.